In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

Google just dropped 4 new Gemini 2.0-series models, with some designed for coding performance and complex prompts and the ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

Some people prefer the term “omnisexual” to “pansexual.” That's because the term pansexuality implies that attraction to people has nothing to do with gender. In contrast, people who ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...